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Abstract 
C-X-C chemokine receptor 4 (CXCR4) is a transmembrane receptor with pivotal roles in cell homing 
and hematopoiesis. CXCR4 is also involved in survival, proliferation and dissemination of cancer, 
including acute lymphoblastic and myeloid leukemia (ALL, AML). Relapsed/refractory ALL and AML are 
frequently resistant to conventional therapy and novel highly active strategies are urgently needed to 
overcome resistance.  
Methods: We used patient-derived (PDX) and cell line-based xenograft mouse models of ALL and AML 
to evaluate the efficacy and toxicity of a CXCR4-targeted endoradiotherapy (ERT) theranostic approach.  
Results: The positron emission tomography (PET) tracer 68Ga-Pentixafor enabled visualization of 
CXCR4 positive leukemic burden. In xenografts, CXCR4-directed ERT with 177Lu-Pentixather 
distributed to leukemia harboring organs and resulted in efficient reduction of leukemia. Despite a 
substantial in vivo cross-fire effect to the leukemia microenvironment, mesenchymal stem cells (MSCs) 
subjected to ERT were viable and capable of supporting the growth and differentiation of non-targeted 
normal hematopoietic cells ex vivo. Finally, three patients with refractory AML after first allogeneic 
hematopoietic stem cell transplantation (alloSCT) underwent CXCR4-directed ERT resulting in leukemia 
clearance, second alloSCT, and successful hematopoietic engraftment.  
Conclusion: Targeting CXCR4 with ERT is feasible and provides a highly efficient means to reduce 
refractory acute leukemia for subsequent cellular therapies. Prospective clinical trials testing the 
incorporation of CXCR4 targeting into conditioning regimens for alloSCT are highly warranted. 
Key words: acute leukemia, microenvironment, C-X-C chemokine receptor 4, in vivo molecular imaging, 
theranostics 
Introduction 
C-X-C-motif chemokine receptor 4 (CXCR4) is a 
G-protein coupled transmembrane receptor that 
regulates a wide spectrum of physiologic processes in 









system function. Knock-out studies in mice have 
demonstrated that absence of CXCR4 or CXCL12 – its 
only known chemokine ligand - is embryonically 
lethal [1, 2]. Binding of CXCL12 to CXCR4 initiates 
G-protein-dependent and -independent signaling 
events, including MAPK, AKT and ERK pathway 
activation, and Ca2+ release from the endoplasmic 
reticulum, which ultimately coordinates chemotaxis, 
homing, proliferation and cell survival [3]. CXCR4 is 
broadly expressed in the hematopoietic system; 
especially hematopoietic stem and progenitor cells 
(HSPCs) need CXCR4 for correct localization and 
retention in the bone marrow (BM) 
microenvironment. Therefore, the CXCR4/CXCL12 
axis is indispensable for homeostasis of the HSPC 
pool in the BM [4]. CXCR4 is also commonly 
expressed or overexpressed in cancer cells, regulating 
proliferation, neo-angiogenesis, resistance to 
chemotherapy and metastasis to organs with high 
amounts of secreted CXCL12 [5, 6]. It has been shown 
for several cancer types, including acute myeloid 
leukemia (AML) that CXCR4 expression is associated 
with adverse prognosis [7]. Therefore, targeting 
CXCR4 with small molecule inhibitors or antibodies is 
being investigated in several clinical trials in various 
cancer types [8]. This concept is particularly 
promising in hematological malignancies, and 
preclinical studies have shown that CXCR4 inhibition 
can both kill cancer cells directly or dislocate them 
from their protective microenvironment, making 
them more susceptible to conventional chemotherapy 
in combined approaches [9-11]. 
In AML, malignant cells arising from immature 
myeloid progenitors or stem cells increasingly occupy 
the BM space as the disease progresses, leading to 
rapidly fatal complications without treatment. Even in 
patients receiving adequate intensive therapy, most 
commonly a combination of cytarabine and 
anthracyclines, overall survival rates 3 years after 
therapy range from 12-66% in younger and 3-33% in 
older adults, depending on prognostic factors [12]. 
Primary refractory disease and relapse after having 
achieved a complete remission are the biggest 
challenges in treating AML. Allogeneic stem cell 
transplantation (alloSCT) is considered the only 
curative option for these patients, and highly active 
conditioning regimens are needed to overcome 
resistance and reduce leukemic burden before 
transplantation. Due to the lack of a standard salvage 
induction regimen, choice of the preferred therapeutic 
strategy remains an individualized decision, often 
varying among different centers [13]. 
Acute lymphoblastic leukemia (ALL) is the most 
common cancer in childhood, with cure rates over 
95% in low risk early B-cell lineage ALL patients [14]. 
However, ALL in adults is more difficult to treat and 
outcomes are worse than in pediatric patients [15]. 
With the bispecific (CD19, CD3) antibody 
blinatumomab and chimeric antigen receptor (CAR) 
T-cells emerging as effective treatments in relapsed 
B-ALL [16], comparably effective novel treatment 
strategies in T-ALL have been lacking so far [17, 18]. 
In both AML and ALL, the BM 
microenvironment is believed to play an essential role 
in protecting leukemic cells from chemotherapy or 
targeted therapies. This protective activity is believed 
to be a major determining factor in the survival of 
malignant cells and relapsing disease [11, 19, 20]. The 
niche is a major source of CXCL12 and this chemokine 
has been shown to induce stem cell quiescence, which 
contributes to resistance of leukemic stem cells to 
chemotherapy [21]. 
We have previously shown that CXCR4-directed 
PET imaging with the novel, human-specific 
CXCR4-binding peptide tracer 68Ga-Pentixafor 
enables the visualization of CXCR4-expressing cells in 
AML and multiple myeloma patients [22, 23]. A 
modified version of Pentixafor, named Pentixather, 
allows labeling with β-emitting radionuclides 
(177Lutetium, 177Lu; 90Yttrium, 90Y) routinely used in 
clinical practice for cancer radiotherapy. This 
facilitates the possibility of a theranostic approach by 
combining CXCR4-directed imaging to select patients 
for CXCR4-directed endoradiotherapy (ERT) with 
Pentixather. This strategy would also allow targeting 
of the malignant cell-supportive BM 
microenvironment supporting malignant cells by 
cross-fire irradiation, which is particularly relevant in 
AML and ALL [11, 19, 20].  
Here, we further develop this concept and apply 
a theranostic approach using ERT with Pentixather in 
preclinical models of T-ALL and AML, and ultimately 
in patients with relapsed AML after first alloSCT, who 
did not respond to conventional therapies. We 
investigate efficacy and toxicity, especially to the BM 
microenvironment, of this novel approach to treating 
leukemia, which provides crucial information for 
future prospective clinical studies. 
Results 
CXCL12/CXCR4 signaling is crucial for ALL 
and AML establishment  
The CXCR4/CXCL12 axis is known to be 
involved in disease initiation, migration and 
treatment resistance in murine AML and ALL models, 
and in patients [20, 24]. We generated T-ALL (ALL0 
and ALL230) and AML (AML356 and AML346) PDX 
mice (Fig. S1, S2 and Table S1) and used an orthotopic 
cell line xenograft model of human AML with 





moderate or enforced CXCR4 expression 
(OCI-AML3-eGFP and OCI-AML3-CXCR4, Fig. S5a, 
b). To evaluate if the CXCR4/CXCL12 axis is 
functionally relevant in ALL and AML xenografts, we 
performed transwell migration assays with AML and 
ALL cells. CXCL12-induced migration and inhibition 
of CXCR4 with the clinically approved CXCR4 
inhibitor AMD3100 (Plerixafor) resulted in significant 
reduction of the migrated cell fraction in OCI-AML3 
cells, and in ALL0 and ALL230 PDX leukemia (Fig. 
1a). Furthermore, immunoblot analysis confirmed 
that phosphorylation of AKT, a known downstream 
target and surrogate marker for CXCR4 activation, 
was induced (Fig. S3). To test if in vivo homing of 
human leukemic blasts to the BM and spleen of NSG 
mice is CXCR4-dependent, we pre-incubated T-ALL 
PDX (ALL230 and ALL0) and OCI-AML3 with the 
established CXCR4-blocking antibody 12G5 or an 
appropriate isotype control antibody, and injected 
these cells into NSG mice (Fig. 1b). After 48 h, BM and 
splenic infiltration by human leukemic cells was 
significantly lower when CXCR4 was blocked with 
12G5, indicating that CXCR4-mediated homing is 
necessary for disease initiation in these acute 
leukemia models (Fig. 1c). 
Thus, these leukemia models are suitable for 
testing CXCR4-directed theranostics in vivo with 





Figure 1. CXCR4/CXCL12 signaling is crucial for establishing acute leukemia PDX. a) Migration of OCI-AML3-CXCR4 and ALL PDX (ALL230 and 
ALL0) towards 100ng/μl CXCL12 alone or combined with 1μM and 10μM AMD3100 (n=3 replicates). b) Schematic of experimental setup for experiments shown 
in c). c) OCI-AML3-CXCR4 and ALL PDX homing in vivo after pre-incubation with CXCR4 antibody clone 12G5 or isotype control. Cells were injected into NSG 
mice and infiltration of organs was assessed after 48h (n=3 mice per group). Statistical significance was determined by two-sided t-tests, *p<0.05, **p<0.01, 
***p<0.001, AMD: AMD3100, BM: bone marrow, Sp: spleen, NSG: NOD-SCID-gamma. 
 





In vivo molecular CXCR4 imaging reflects 
surface expression of CXCR4 and represents 
the first step in CXCR4 theranostics 
We next sought to determine if leukemic PDX 
cells expressing CXCR4 could be imaged in vivo with 
the human-specific CXCR4-binding peptide PET 
tracer 68Ga-Pentixafor as an initial component of 
CXCR4 theranostics. The grafts of the employed PDX 
models of T-ALL and AML clearly displayed different 
levels of CXCR4 surface expression (Fig. 2a). Upon 
NSG recipient injection with PDX, peripheral blood 
(PB) blast counts were monitored with flow 
cytometry. 68Ga-Pentixafor PET imaging was 
performed when human blasts could be detected in 
PB or when mice displayed symptoms of leukemia 
(weight loss, behavioral abnormalities). 
68Ga-Pentixafor enabled approximate visualization of 
leukemic burden of T-ALL (ALL230, ALL0) and AML 
PDX (ALL356) in spleens and bones of NSG mice (Fig. 
2b) and correlated with CXCR4 surface expression of 
PDX (Fig. 2c). Histology and immunohistochemistry 
of imaged mice confirmed CXCR4 expression on 
human infiltrating blasts (Fig. 2d). 69Ga-Pentixafor 
PET images of control NSG mice without leukemic 
burden are shown in Fig. S4 in different intensities. 
To determine if Pentixather, the structurally 
modified therapeutic counterpart of Pentixafor, binds 
to human leukemia cells in vivo, we injected AML356 
PDX recipients with 125Iodine-Pentixather three, four 
and five weeks after injection of PDX cells. Binding of 
Pentixather to splenic AML blasts was detected by 
ex vivo autoradiographic imaging of spleens. 
Progressive splenic infiltration could be visualized by 
autoradiography, indicating that 125I-Pentixather 
binds to AML356 PDX in vivo (Fig. 2e). 
Thus, the CXCR4-directed therapeutic peptide 
Pentixather represents a pre-clinically applicable 
means to target human CXCR4+ PDX in vivo, and may 
serve as a surrogate imaging diagnostic for assessing 
human leukemia infiltration in BM and other organs.  
 
 
Figure 2. CXCR4 diagnostics in preclinical models of acute leukemia. a) CXCR4 surface expression in ALL and AML PDX (n=3 replicates). b) 
Representative PET images of 68Ga-Pentixafor scans in mice bearing ALL and AML PDX. Red arrows: spleen, white arrows: bone marrow (n=6 ALL230, n=6 ALL0, 
n=5 AML356). c) Correlation between Ga-Pentixafor PET uptake and mean CXCR4 surface expression. d) HE staining and CXCR4 immunohistochemistry of 
spleens of ALL230, ALL0 and AML356 mice. Scale bars: 50 μm. e) Representative images of 125I-Pentixather autoradiography of AML356 spleens. MFI: mean 
fluorescence intensity, HE: Hematoxylin and eosin, r: Pearson correlation coefficient. 





Therapeutic CXCR4-targeted peptide 
effectively reduces leukemia in PDX mice 
To test the efficacy of CXCR4 targeting in vivo we 
chose peptide labeling with the well-established 
therapeutic beta-emitter 177Lu [25, 26]. Two CXCR4high 
T-ALL PDX models and two cell line models of AML 
(OCI-AML-eGFP and OCI-AML-CXCR4) with 
different infiltration characteristics of BM, spleen and 
blood (Fig. S1) were subjected to 177Lu-Pentixather 
(Lu-P) treatment (d0) or unlabeled Pentixather as 
control. Mice were sacrificed 3 and 7 days after 
injection of Lu-P (Fig. 3a). To determine the 
distribution of Lu-P in treated mice, we measured 
radioactivity in PB, BM and spleen of treated mice and 
found that Lu-P distributed to and strongly 
accumulated in leukemia-harboring organs (Fig. 3b). 
In the ALL230 cohort, mice in the control group 
had large spleens (254.7 mg and 551.7 mg in the d3 
and d7 groups, respectively). Lu-P therapy 
significantly reduced spleen size and weight in 
treated animals. In mice receiving the less aggressive 
ALL0 PDX, spleens were less enlarged ~4 weeks after 
PDX injection. Again, Lu-P therapy resulted in 
significantly reduced spleen weight as compared to 
control mice (Fig. 3c, d). In order to investigate ALL 
involvement of PB as well as spleen and BM, we 
performed flow cytometry. ALL230 displayed 
pronounced reduction of blast populations in spleen, 
BM and PB (Fig. 3e, f). Histology and 
immunohistochemistry of spleen and BM of control 
mice revealed an extensive infiltration with CXCR4+ 
neoplastic cells. In contrast, in all organs of 
Lu-P-treated mice, cellularity was significantly 
reduced and leukemic cells were effectively targeted 
by ERT (Fig. 3g). In BM and spleen of heavily 
infiltrated mice, although single neoplastic blasts 
were still detectable, hemorrhage and necrotic tissue 
damage were apparent, indicating effective targeting 
of the infiltrative tumor cell population as a result of 
therapy. 
In summary, these experiments show that 
CXCR4-directed ERT effectively targeted CXCR4+ 
tumor cells and reduced leukemic burden in T-ALL 
PDX recipient mice. The data also indicate that 
damage occurred to the remaining functional BM, 
most likely as a result of cross fire effects by Lu-P. 
To answer the question whether the intensity of 
CXCR4 surface expression affected treatment efficacy, 
we used OCI-AML3-CXCR4, with a ~2.5-fold 
overexpression of surface CXCR4 (Fig. S5a) as 
compared to empty vector control-eGFP transduced 
cells. These cells were injected intravenously into NSG 
mice to establish xenografts, followed by treatment 
with Lu-P or unlabeled Pentixather. Three days after 
treatment we observed a significant reduction of 
spleen weight irrespective of the level of CXCR4 
expression (moderate vs. enforced) (Fig. S5c). 
Importantly, treatment of AML346, the PDX line with 
the lowest CXCR4 expression, did not result in 
reduction of leukemic burden (Fig. S6.). These 
experiments with AML models with low (AML346), 
moderate (OCI-AML3-eGFP) and elevated 
(OCI-AML3-CXCR4-eGFP) CXCR4 surface expression 
suggested that a certain degree of target expression, 
i.e., CXCR4 surface expression, is necessary for 
treatment efficacy. This finding should be relevant 
with regard to clinical benefit for AML patients with 
various extent of CXCR4 expression. 
Cross-fire originating from Lu-P targeting 
impairs normal HSPCs and the BM niche 
We hypothesized that, owing to the β-emitting 
properties of 177Lu, radionuclide targeting of CXCR4 
expressing leukemic cells would result in damage to 
the surrounding tissue, including murine HSPCs and 
other cellular components of the BM niche. The PDX 
models in combination with a targeting peptide 
specific for human CXCR4 [27, 28] thus provided an 
ideal model to address cross-fire effects on murine 
recipient HSPCs and the host cellular 
microenvironment. 
To directly assess damage inflicted to murine 
HSPCs, we performed colony forming unit (CFU) 
assays with murine growth factors on BM harvests of 
ERT-treated and control ALL230 and ALL0 PDX mice 
(Fig. 4a). In both PDX models, the proliferative 
potential of murine BM HPCs was significantly 
reduced with treatment. In ALL230 mice, which had 
subtotal infiltration of the BM by human ALL (Fig. 
3g), Lu-P treatment even resulted in complete ablation 
of CFU growth (Fig. 4b). Using flow cytometry, we 
observed a significantly reduced fraction of lineage 
negative (Lin-), Sca1 positive, cKit positive stem cells 
(LSKs), and BM myeloid progenitors (MPs) (Fig. 4c, 
gating strategy in Fig. S7). In Lu-P treated mice, LSKs 
and MPs were almost completely absent in flow 
cytometry, further emphasizing the toxicity of 
radioactive targeting for the neighboring 
hematopoietic population.  
To test if the BM niche, especially the MSC 
population crucial for reconstitution of 
hematopoiesis, is affected by ERT, we isolated and 
analyzed endosteal niche cells from collagenase 
treated bones of Lu-P treated and untreated mice and 
performed flow cytometry analyses as described 
earlier [29, 30]. MSC were still present in both 
ERT-treated and control mice after isolation of 
endosteal niche cells (Fig. 4d). To further assess if the 
BM MSC population was still viable after Lu-P 





treatment, we performed CFU-F assays to isolate 
MSCs from bones of treated and control mice 
(representative images in Fig. S8). MSCs are defined 
as adherent cells emerging from bones, which form 
colonies and proliferate in vitro [31]. Colony numbers 
were not significantly different in Lu-P vs. control 
with a trend towards reduction in the treatment group 
(Fig. 4e). Further growth of the isolated MSCs was 
significantly reduced in the Lu-P group, indicating 




Figure 3. CXCR4-directed theranostics effectively reduce leukemia burden. a) Schematic of experimental setup. b) Activity accumulation in percent of injected dose 
per gram (%iD/g) of Sp, bone and PB 3d post injection of Lu-P in mice bearing ALL PDX or OCI-AML3 cells overexpressing CXCR4 or eGFP empty vector (n=4 for ALL230, 
OCI-AML3 CXCR4, n=3 for ALL0, OCI-AML3 eGFP). c) Spleen weight of ctrl and Lu-P treated ALL0 and ALL230 mice after 3 and 7d (n=3 for ALL0 3d, n=4 for all other groups). 
d) Representative images of ALL230 spleens treated for 3d with ctrl or Lu-P. e) Representative FACS plots of Sp, BM and PB of ALL230 mice treated for 7d with ctrl or Lu-P, 
gated on propidium-iodide negative, live cells. Human ALL cells are human CD38 positive and murine CD45 negative. f) Quantification of e), percentage of human blasts is shown. 
g) Sp and BM histology of ALL230 mice treated with ctrl or Lu-P with HE stain, CXCR4 and CD3 immunohistochemistry, scale bar length in μm as indicated. Statistical significance 
was determined by two-sided t-tests, *p<0.05, **p<0.01, ***p<0.001, ctrl: control, Lu-P: 177Lu-Pentixather, PB: peripheral blood. 






Figure 4. Cross-fire effect on non-malignant hematopoiesis and BM microenvironment. a) Schematic of experimental setup. b) Methylcellulose CFU 
assay for murine progenitors of BM from ALL230 and ALL0 mice 3d after treatment with ctrl or Lu-P (n=4 mice for ALL230, n=3 mice for ALL0). c) Flow cytometry 
of BM isolated from ctrl and Lu-P treated ALL0 mice. LSKs and MPs were analyzed (n=3 mice per group). d) Comparison of MSCs (Sca1+, ALCAM- fraction of CD45-, 
Ter119-, CD3-, live cells) of treated and control ALL0 mice (n=3 mice per group). e) Quantification of CFU-F colony numbers (small: <20 cells, medium: 20-200 cells, 
large >200 cells) of ctrl and Lu-P treated ALL230 mice (n=4 mice per group). f) Total number of stromal cells from d) after 18d of culture. g) Coculture of MSCs from 
Lu-P and ctrl ALL20 mice (3d) and lineage- BM cells from WT NSG mice. LSKs, MPs, Gr1+CD11b+ granulocytes and Gr1medCD11b+ monocytes were analyzed after 
7d of coculture (n=3 for ctrl, n=4 for Lu-P). h) Representative microscopic images of coculture experiment as described in g). Statistical significance was determined 
by two-sided t-tests, *p<0.05, **p<0.01, ***p<0.001, colony forming unit (CFU), LSKs: Lineage-, Sca1+, cKit+ cells, MPs: myeloid progenitors, MSCs: mesenchymal 
stem cells, CFU-F: colony forming unit-fibroblasts. 
 
Support by the BM niche is essential for 
engraftment of HSPCs after myeloablative 
conditioning. We therefore investigated whether the 
isolated MSCs were still supportive of healthy HSPCs 
by co-culturing MSCs with MACS-purified immature 
(Lin-) murine HSPCs and analyzed MP and LSK 





number and frequency, and differentiation into 
mature myeloid cells. In both Lu-P treated and control 
stroma co-cultures, MPs and LSKs were supported 
and differentiation into granulocytes and monocytes 
was induced (Fig. 4g). Furthermore, HSPCs in 
co-culture formed cobblestone-like areas on both 
Lu-P-treated and control stroma (Fig. 4h). To model 
the effect of Lu-P on human BM MSCs, a small subset 
of which are known to express CXCR4 [32], we 
isolated MSCs from BM samples of healthy 
individuals and treated MSCs with Lu-P or unlabeled 
Pentixather. After treatment, we co-cultured purified 
healthy human CD34+ cells with the MSCs and 
assessed viability and potential to form colonies in 
methylcellulose (Fig. S9). There was no significant 
impairment of Lu-P pre-treated MSCs’ ability for 
subsequent support of normal CD34+ cells. 
In summary, the cross-fire effect caused by 
β-emitter ERT results in significant damage to HSPCs 
and substantially targets proliferative activity of BM 
niche cells, while the functional capacity of stromal 
cells to support the growth and differentiation of in 
vitro co-cultured healthy immature hematopoietic 
cells was not abrogated. 
Pentixather treatment in very advanced 
human acute leukemia: ERT followed by 
second alloSCT 
Finally, the concept of targeting CXCR4 in acute 
leukemia by ERT was translated into a clinical setting. 
Three patients with relapsed AML were referred for 
assessment of further treatment option, e.g., 
Pentixather treatment. All patients were heavily 
pretreated, including first alloSCT, but had 
experienced early relapse (for patient characteristics 
and previous treatments see Table S2). Given the lack 
of alternative treatment options in this advanced 
disease stage, experimental CXCR4-directed 
treatment was offered on a compassionate use basis 
(German Drug Act, §13,2b) in compliance with §37 of 
the Declaration of Helsinki. All subjects gave written 
informed consent prior to therapy. 
Patient #1 (46-year-old male) presented with 
AML without maturation (AML M1). After standard 
induction chemotherapy and salvage therapy due to 
primary refractory disease first alloSCT was 
performed. Three months after SCT, relapse was 
diagnosed and the patient was referred. Given the 
early relapse, investigation of CXCR4 expression as a 
putative therapy target was considered. 
68Ga-Pentixafor-PET demonstrated receptor 
expression (Fig. S10a), which qualified for 
CXCR4-targeted ERT. Pre-therapeutic dosimetry 
resulted in tolerable activities of 5 GBq (with the 
kidneys being the dose-limiting organ) of 
90Y-Pentixather (Y-P), and achievable BM doses of ~11 
Gy. 90Y as radionuclide was chosen due to its higher 
energy and longer range as compared to 177Lu, and 
because its shorter half-life allows earlier SCT. ERT 
with 4.72 GBq of Y-P was performed and well 
tolerated. In order to maximize the therapeutic effect 
of ERT, we decided to increase internal radiation by 
adding a course of 153Sm-labelled ethylene diamine 
tetramethylene phosphonate (EDTMP), which, in 
contrast to Pentixather, localizes to the surface of 
cortical and trabecular bone, to the conditioning 
regimen. Based on previous studies investigating 
153Sm-EDTMP for BM ablation [33, 34], 15.9 GBq was 
intravenously administered five days after Y-P and 
resulted in additional BM irradiation as high as 8 Gy 
for the red marrow and 53 Gy in osteogenic cells in 
the cortical bones. Conditioning was completed by 
fludarabine (40 mg/m2; d-8 to d-5), thiotepa (5 mg/kg 
body weight; d-4; twice), melphalan (70 mg/m2; d-3 to 
d-2) and antithymocyte globulin (ATG; 10/20/30 
mg/kg; d-10 to d-8). 19 days after the initial Y-P 
treatment, the patient received a second alloSCT (day 
0). Besides prolonged epistaxis in aplasia requiring 
temporary intubation, he did not experience major 
complications. On day +11, recovery of neutrophils, 
on day +14, recovery of thrombocytes could be 
recorded (Fig. 5d). On day +30, donor chimerism in 
peripheral blood was 99.89%. 
Patient #2 (67-year-old female) suffered from 
therapy-related AML (t-AML) that arose after 
exposure to polychemotherapy for breast cancer 18 
years earlier. After induction therapy and first 
alloSCT (Table S2) the patient was in complete 
remission for 16 months until relapse. At the time of 
presentation, 50% AML infiltration of the BM as well 
as multiple extramedullary disease (EMD) lesions in 
the soft tissue of the pelvis and abdomen were 
present. 68Ga-Pentixafor PET revealed a rather modest 
receptor expression of the BM but intense tracer 
uptake in all EMD lesions (Fig. S10b). Given the lack 
of established treatment options, a second alloSCT 
after a combined conditioning approach using Y-P for 
both the intra- as well as especially EMD lesions 
(administered activity of 4.5 GBq; d-20), 188Re-labelled 
anti-CD66 antibodies for BM ablation (5.2 GBq; d-14) 
and conventional agents including rituximab (375 
mg/m2; d-6), total body irradiation (TBI, 2 Gy; d-5); 
ATG (10 mg/kg; d-4; resulting in anaphylactic shock), 
and melphalan (70 mg/m2; d-3 to d-2) was chosen. 
Pre-therapeutic dosimetry in this patient yielded 
estimated BM doses of up to 17 Gy and EMD doses of 
23 Gy. Achieved doses for 188Re-anti-CD66 antibodies 
could not be calculated due to technical problems; 
however, post-therapeutic whole-body scintigraphy 
proved high antibody retention in the bone marrow 





(Fig. S10b). Unfortunately, this patient died after 
hematological recovery from septic complications on 
day +17 after second SCT (Fig. 5d). Chimerism 
analysis had not yet been performed. 
Patient #3 (39-year-old male) had been 
diagnosed with AML M0 nine months prior to 
presentation (Table S2). He had experienced leukemia 
relapse only five months after haploidentical first 
alloSCT (Fig. 5a-c) and was referred for salvage 
therapy. In analogy to patient #2, combined 
CXCR4-directed ERT (with 2.7 GBq of Y-P; d-33) and 
anti-CD66 therapy (with 7.7 GBq of 188Re-anti-CD66 
antibodies; d-28) as part of conditioning prior to 
second alloSCT was performed and resulted in red 
BM doses of 20 Gy. During aplasia, severe mucositis 
and a septic episode could be successfully managed. 
After neutrophil reconstitution on d+20, 99.9% 
peripheral blood donor chimerism were recorded on 
d+26. The patient was discharged the day after. 
Repeated BM biopsy 6 months after alloSCT 
confirmed complete remission.  
Discussion 
Our data provide first evidence for efficacy of 
CXCR4-directed ERT with Pentixather in preclinical 
models of T-ALL and AML, and a limited number of 
patients treated within individual therapy approaches 
for very advanced disease.  
 
 
Figure 5. Proof-of-concept evaluation in advanced human acute leukemia: ERT followed by allogeneic stem cell transplantation. a) 
68Ga-Pentixafor PET imaging and planar whole-body scintigraphic images 24h and 72h after injection of 200 MBq Lu-P in patient 3 (activity injected for pre-therapeutic 
dosimetry). b) Blast CXCR4 surface expression in flow cytometry in patient 3 (gated on CD45med/SSClow blasts) c) HE stain, CD34 and CXCR4 BM 
immunohistochemistry of patient 3, scale bars: 50 μm. d) Leukocyte counts and % donor chimerism of patients undergoing Y-Pentixather based conditioning and 
allogeneic stem cell transplantation. MIP: maximum intensity projection, Sm: 153Samarium-EDTMP, Re-CD66: 166Rhenium-anti-CD66 antibody. 





When AML or ALL relapse or are refractory to 
treatment, a multitude of challenges arises. Both 
relapse and refractoriness are a manifestation of cells 
having developed resistance to therapy or 
re-emerging after a period of dormancy. In such a 
scenario, salvage therapy and pre-transplant 
conditioning needs to be of the highest possible 
efficacy with regard to eradicating leukemic cells 
without compromising engraftment or causing 
excessive or irreversible damage to 
non-hematopoietic organs, which would further 
increase treatment-related morbidity and mortality.  
Despite the prominent role of cell-intrinsic 
mechanisms in T cell as well as myeloid HSPC 
transformation, ALL/AML cell growth is not fully cell 
autonomous. In the BM, T-ALL lymphoblasts 
establish stable contacts with vascular endothelial 
niche cells expressing CXCL12 and are dependent on 
cues from the microenvironment for cell proliferation 
and survival [20, 35, 36]. A similar role for the 
CXCR4/CXCL12 axis has been established for AML 
[11, 19, 37], indicating that CXCR4/CXCL12 activity 
in the BM microenvironment marks a highly 
beneficial local sanctuary for ALL and AML cells. 
Despite tremendous efforts and the fact that several 
drugs are available and have already entered the 
clinical phase of development, neither small molecule 
or peptide inhibitors nor CXCR4-targeted antibodies 
have yet shown convincing efficacy [38]. There are 
several reasons why such pharmacological 
approaches (antibodies, inhibitors) may not result in 
long-term benefit. Potential mechanisms of resistance 
include downregulation or internalization of surface 
CXCR4, heterogeneous expression on cancer cells 
resulting in incomplete targeting, and potential 
competition with locally increased CXCL12 
concentrations [39, 40]. 
Our therapeutic preclinical PDX data indicate 
that the CXCR4 ERT concept provides substantial 
efficacy via the cross-fire effect, overcoming the 
requirement that every single cancer cell is reached 
und thus also providing a strong niche-targeted 
impact. This however comes with a major intricacy, 
namely targeting basically all niches where 
CXCR4-expressing cells, whether malignant or not, 
reside. Due to the limited number of patients treated 
with the experimental protocol presented in this 
work, and the fact that only AML patients received 
Pentixather ERT, we cannot conclude at this time 
whether the level of expression of CXCR4 is 
predictive of efficacy or toxicity. The preclinical data 
regarding level of CXCR4 expression (Fig. 2a) and 
correlation of CXCR4 expression with 68Ga-Pentixafor 
PET imaging however could hint towards a 
correlation between organ-bound dosage and local 
effectiveness as well as toxicity (Fig. 3, Fig. 4, Fig. S9). 
Direct and indirect targeting of the interaction of 
leukemic cells with cellular components of the BM 
microenvironment represents an attractive strategy to 
induce the best possible remission before 
immunological intervention. In fact, various studies 
have shown that AML patients who enter 
conditioning and alloSCT have significantly better 
survival as compared to those with residual disease 
[41]. Severe impairment of the hematopoietic niche 
before alloSCT may result in severely prolonged 
pancytopenia or engraftment failure. Therefore, 
careful dosage and detailed preclinical evaluation of a 
potential niche-targeting agent is warranted. Our 
study of the BM microenvironment of PDX recipient 
mice, whose HSPC and MSC cannot bind Pentixather, 
and our experiments with human MSC showed that 
the number of niche cells is not affected by treatment. 
However, proliferation of niche cells after in vivo ERT 
is severely impaired. Despite this strong collateral 
damage observed within the BM microenvironment 
of PDX recipient mice, whose HSPC and MSC cannot 
bind Pentixather, patients receiving radionuclide- 
labeled Pentixather showed engraftment well within 
the expected range. Clearly, only a prospective clinical 
trial will allow determining the full extent of short 
and long-term effects of Pentixather treatment on the 
BM niche and other organs. Our results suggest that 
despite proliferative impairment, recipient MSC are 
well capable of supporting HSPC maintenance when 
cultured ex vivo.  
Uptake of the imaging tracer Pentixafor within 
the liver of mice undergoing 68Ga-Pentixafor PET 
imaging is not reflected in patients [42]. Due to the 
high affinity to human compared to murine CXCR4 
[28], this phenomenon is most likely due to unspecific 
binding or an idiosyncrasy of the murine metabolism 
of Pentixafor.  
TBI has been applied in pre-transplant regimens 
as early as the 1960s, and is still used routinely in the 
treatment of leukemia due to its efficacy and ability to 
penetrate sanctuary sites [43]. Toxicity to 
non-hematopoietic organs is a major limitation of this 
technique. Approaches delivering radioactivity 
directly and selectively to the hematopoietic system, 
for instance radiolabeled antibodies against CD45 or 
CD66, have been used in pre-transplant conditioning 
[44, 45]. Targeting CXCR4 with a radioactive peptide 
might facilitate killing particularly therapy-resistant 
and otherwise difficult to treat leukemic cells in their 
protective niche. Especially in T-ALL, CXCR4 was 
recently shown to be essential for leukemia-initiating 
cells and maintenance of the disease in the BM [20, 
24], further supporting potential benefit of CXCR4 
targeting in this malignancy. We would expect that 





the same applies for CXCR4+ AML. We also would 
expect that Pentixather ERT could be provided to 
patients in need of non-chemotherapy salvage 
therapy before alloSCT who are not candidates for 
full-dose TBI due to age and/or comorbidities.  
Due to the flexibility and various possibilities to 
label Pentixather, the choice of the radionuclide is not 
limited to 177Lu or 90Y [26]. Alpha emitters like 
213Bismuth or 225Actinium have a much shorter range 
and deliver higher amounts of energy, potentially 
increasing specificity of targeting tumor cells and 
their immediate surroundings [46, 47]. We chose 177Lu 
in animal experiments and 90Y in patients due to 
different maximum ranges (0.8 mm and 11 mm, 
respectively), with the rationale to deliver appropriate 
doses to affected organs and spare healthy tissue. 
Other theranostic strategies currently being used in 
clinical practice include the treatment of midgut 
neuroendocrine tumors using 177Lu-DOTATATE, 
with excellent results in a phase 3 trial [48]. 
For a CXCR4-directed theranostic concept, 
screening with 68Ga-Pentixafor PET/CT or MRI will 
determine patients eligible for incorporation of 
Pentixather treatment in the conditioning regimen. A 
clinical phase I/II study (COLPRIT, EudraCT: 
2015-001817-28) to evaluate safety of a 
Pentixafor/Pentixather based concept in the 
treatment of relapsed/refractory Non-Hodgkin 
lymphoma and multiple myeloma followed by 
autologous SCT is planned to be performed. Whether 
CXCR4 PET imaging is required in leukemia or can be 
replaced by flow cytometry of BM needs to be 
evaluated in the controlled prospective clinical 
setting. Based on the data presented here however, a 
clinical trial testing the incorporation of Pentixather 
into conditioning regimens before alloSCT is urgently 
warranted.  
Materials and Methods 
Cell culture and cell lines 
The human AML cell line OCI-AML3 was 
cultured in high glucose (4.5 g/L) DMEM 
supplemented with 10% FCS, 100 U/mL penicillin 
and 100 µg/mL streptomycin. Cells were obtained 
from the German Collection of Microorganisms and 
Cell Cultures (DSMZ, Leibniz, Germany) and 
routinely re-authenticated. Cells were maintained at 
37°C in a 5% CO2 humidified atmosphere. All media 
and supplements were obtained from Gibco/Life 
Technologies (Carlsbad, CA, USA). CXCR4 
overexpression was achieved by lentiviral 
transduction of OCI-AML3 cells with 
pHIV-CXCR4-eGFP, with cDNA of human CXCR4 
cloned into pHIV-eGFP (Addgene plasmid ID 
#21373).  
Migration assay 
Migration assays were performed as described 
previously [23]. Briefly, cells were incubated with 
AMD3100 (Selleckchem, Houston, TX, USA) or 
DMSO and placed in the top chamber of transwell 
plates with 5 µm pore size (Corning Inc., Corning, NY, 
USA) with 100 ng/mL CXCL12 in the lower chamber 
(R&D Systems, Minneapolis, MN, USA). Cells were 
then incubated at 37°C for 4 h and the total number of 
cells migrated to the lower chamber was measured 
using CountBright beads (Thermo Fisher, Waltham, 
MA, USA). 
CFU, CFU-F and MSC coculture 
For CFUs, BM of treated and untreated mice was 
mixed with methylcellulose with murine growth 
factors M3434 (Stemcell Technologies, Vancouver, 
Canada) and processed according to the 
manufacturer’s protocol. 
CFU-Fs (MSCs) were isolated by placing bone 
fragments in stromal cell culture medium and 
cultured on plastic surfaces coated with 0.1% gelatin 
as described earlier [49]. Lineage negative cells (2500 
total) from BM of NSG mice were isolated by MACS 
(magnetic cell separation, lineage depletion kit, 
Miltenyi Biotec, Bergisch Gladbach, Germany) and 
cultured on confluent MSCs for 7 days. 
Flow cytometry  
Experiments were performed on a Cyan ADP 
(Beckman Coulter, Brea, CA, USA). For surface 
markers used in routine diagnostics (Fig. S2), a 
Cytomics FC500 flow cytometer was used (Beckman 
Coulter). The following antibodies were used: human 
CD3-FITC (clone UCHT1), human CD4-PECy5 (clone 
13B8.2), human CD5-PECy7 (clone BC1a), human 
CD7-PECy5 (clone 8H8.1), human CD8-ECD (clone 
SFC/Thy2D3), human CD13-PE (clone SJ1D1), human 
CD14-PE (clone RM052), human CD15-FITC (clone 
80H5), human CD30-PE (clone HRS-4), human 
CD33-PE (clone D3HL60.251), human CD34-FITC 
(clone 581), human CD56-PE (clone N901(NHK-1)), 
human CD64-FITC (clone 22), human CD117-PE 
(clone 104D2D1), human HLADR-ECD (clone 
Immu357), human MPO-FITC (clone CLB-MPO-1), 
human TdT-FITC (HT1,HT4,HT4,HT9) from Beckman 
Coulter; human CXCR4-PE/BV421 (clone 12G5), 
BV421-isotype, human CD38-APC (clone HB7) from 
BD Biosciences (Franklin Lakes, NJ, USA), human 
CD45-eFluor450 (clone HI30), murine 
CD45-FITC/APC-eFluor780 (clone 30F11), murine 
CD3-PECy5.5 (clone 145-2C11), murine CD4-PECy5 
(clone GK1.5), murine CD8a-PECy5 (clone 53-6.7), 
murine CD117/cKit-PE (clone 2B8), murine 





Sca1-PECy7 (clone D7), mB220-PECy7 (clone 
RA3-6B2), mGr1-PE (clone RB6-8C5), 
mCD11b-APC-eFluor780 (clone M1/70), murine 
Ter119-eFluor450 (clone TER-119), murine 
CD166/ALCAM-PE (clone ALC48), murine 
CD31-APC (clone 390), murine Lineage (CD3, B220, 
Gr1, CD11b, Ter119)-biotin from eBioscience (San 
Diego, CA, USA). Cells were incubated with 
respective antibodies and buffer (phosphate buffered 
saline with 0.5% bovine serum albumin) in 4°C in the 
dark for 15 minutes. Data were analyzed using FlowJo 
(Ashland, OR, USA). 
Immunohistochemistry 
Human and mouse tissues were fixed in 10% 
neutral-buffered formalin solution for maximum 48 h, 
dehydrated under standard conditions (Leica 
ASP300S, Wetzlar, Germany) and embedded in 
paraffin. BM specimen were decalcified in Osteosoft® 
(Merck Millipore, Darmstadt, Germany). Serial 2 µm 
thin sections prepared with a rotary microtome 
(HM355S, ThermoFisher Scientific, Waltham, USA) 
were collected and subjected to histological and 
immunohistochemical analysis. Hematoxylin-Eosin 
(H.-E.) staining was performed on deparaffinized 
sections with Eosin and Mayer’s Haemalaun 
according to a standard protocol. For 
immunohistochemistry, slides were deparaffinized in 
xylene and rehydrated by alcohol washes of 
decreasing concentration (100%, 96%, 70%). After 
heat-induced antigen retrieval (target retrieval 
solution, pH 6 (Dako, Glostrup, Denmark, S1699)), 
unspecific protein and peroxidase binding was 
blocked with 3% hydrogen peroxide and 3% normal 
goat serum (Abcam, Cambridge, UK, 7481). 
Immunohistochemistry was performed with a Dako 
autostainer (Dako, Glostrup, Denmark) (CD3, 
CXCR4) or a Ventana Benchmark XT (Roche, Basel, 
Switzerland) (CD34) using antibodies against CD3 
(clone SP7, DCS, Hamburg, Germany, CI597C01), 
CD34 (human specimen, (clone QBEnd/10, 
CellMarque, Darmstadt, Germany) and CXCR4 (clone 
UMB-2, Abcam, Cambridge, UK, 124824). For 
antibody detection, the Dako Envision-HRP rabbit 
labeled polymer (Dako, Glostrup, Denmark) or the 
UltraView Detection Kit (Roche, Basel, Switzerland) 
was used. Antibody binding was visualized by 
diaminobenzidine (DAB) giving a brown precipitate 
(Medac Diagnostica, Wedel, Germany, BS04-500). 
Counterstaining was performed using hematoxylin 
and slides were dehydrated by alcohol washes of 
increasing concentration (70%, 96%, 100%) and xylene 
and coverslipped using Pertex® mounting medium 
(Histolab, Goeteborg, Sweden, 00801).  
Mice and patient-derived xenografts  
For xenograft experiments, immuno-
compromised NOD.Cg-Prkdcscid Il2rgtm1WjI/SzJ (NSG) 
mice were purchased from Charles River (Charles 
River Laboratories Inc., Wilmington, MA, USA) and 
kept in a pathogen free environment in our animal 
facility. All experiments were approved by the 
regional authorities (Regierung von Oberbayern) in 
compliance with the German law on the protection of 
animals. Patient-derived xenograft models (PDX) 
were generated as previously described [50, 51]. 
Synthesis of Pentixafor and Pentixather 
Synthesis of all used radiopharmaceuticals was 
performed in a fully automated, GMP-compliant 
procedure using a GRP® module (SCINTOMICS 
GmbH, Fürstenfeldbruck, Germany) equipped with 
disposable single-use cassette kits (ABX, Radeberg, 
Germany), using the method [28, 52] and 
standardized labeling sequence previously described 
[53]. Prior to injection, the quality of 68Ga-Pentixafor 
was assessed according to the standards described in 
the European Pharmacopoeia for 68Ga-Edotreotide 
(European Pharmacopoeia; Monograph 01/2013:2482; 
available at www.edqm.eu). 
CXCR4 PET imaging in mice 
PET imaging of leukemia-bearing mice was 
performed as previously described [23]. Briefly, mice 
were anesthetized with isoflurane and 12 MBq 
68Ga-Pentixafor was injected via the tail vein. After 75 
min, static images were obtained for 15 min on a 
µPET-system (Inveon, Siemens, Erlangen, Germany).  
Pentixather treatment in vitro 
Whole bone marrow from healthy donors was 
cultured in DMEM (1 g/L Glucose) with 10% pooled 
human platelet lysate, Heparin (50 U/mL), 2 mM 
L-Glutamine, 1% Penicillin/Streptomycin to isolate 
plastic-adherent MSCs for in-vitro Pentixather 
treatment. Briefly, cells were treated for 10 min, 1 h 
and 6 h in 12-well plates with 1.5 MBq/mL Lu-P 
(comparable to 30 MBq distributed in a mouse 
weighing 20 g) or unlabeled Pentixather. For 
co-culture, CD34+ cells were isolated with CD34 
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) via magnetic separation and ~1.5x104 cells 
were added to treated/control MSCs. After 4d of 
co-culture, flow cytometry and colony forming unit 
assays (StemMACS HSC-CFU complete with EPO, 
Miltenyi Biotec) were performed. 
Pentixather treatment in mice 
When leukemia was apparent in peripheral 
blood (4-5 weeks after injection), mice were subjected 





to treatment with Lu-P or ctrl (unlabeled Pentixather) 
via tail vein injection, and then transferred to a 
radiation-restricted area for surveillance before they 
were sacrificed and relevant organs were harvested 
for further analysis. Mean injected radioactivity in 
ALL230, ALL0, OCI-AML3-eGFP and 
OCI-AML3-CXCR4 mice was 27.5 MBq, 23.4 MBq, 
26.2 MBq and 25.2 MB1, respectively. Sample sizes 
were as follows: n=4 treated with Lu-P for 3d, n=4 
treated for 7d with respective controls for ALL230, 
n=3 treated for 3d, n=4 treated for 7d with respective 
controls for ALL0, n=4 treated and n=4 control for 
AML346, n=3 treated and n=3 control for 
OCI-AML3-pHIV, n=4 treated and n=4 control for 
OCI-AML3-CXCR4. 
Pentixather-based conditioning therapy in 
patients 
Three patients with relapsed AML after alloSCT 
were referred for further therapy. Given the lack of 
alternative treatment options in this advanced disease 
stage, experimental CXCR4-directed treatment (with 
additional internal irradiation with 153Sm-EDTMP or 
188Re-anti-CD66 antibodies for BM ablation) was 
offered on a compassionate use basis (German Drug 
Act, §13,2b) in compliance with §37 of the Declaration 
of Helsinki. Treatment was approved by the clinical 
ethics committee of our institution. All subjects gave 
written informed consent prior to therapy. 
A pre-therapy dosimetry study using SPECT/CT 
and serial planar imaging was performed in patients 
scheduled for CXCR4-directed ERT after intravenous 
injection of ~200 MBq of Lu-P. This was done to i) 
record sites of unexpected tracer accumulation that 
may denote potential toxicity, ii) determine the organ 
radiation doses, and iii) to estimate the achievable 
tumor doses. The absorbed doses in tumors and 
organs were assessed by analyzing regions of interest 
in multiple planar total body images to obtain 
pharmacokinetic data and a single SPECT/CT scan to 
scale the pharmacokinetic curve.  
All images were acquired using dual head 
gamma cameras (Siemens Symbia E for planar 
imaging, Siemens Symbia T2 calibrated from 
phantom measurements with 177Lu activity standards 
for SPECT/CT acquisition) equipped with medium 
energy collimators. Pharmacokinetic data were fitted 
by bi-exponential functions. SPECT/CT data were 
reconstructed using a 3D-OSEM (6 subsets, 6 
iterations, Gauss 6mm) algorithm with corrections for 
scatter and attenuation to obtain absolute activity 
quantification in voxels sized 0.11 cm³. Estimates for 
the absorbed doses from treatment with Y-P were 
calculated from the 1 mL volumes with highest 
activity concentrations in dosimetry with Lu-P. 
Based on their individual dosimetry, patients 
were treated by intravenous injection of 90Y- labeled 
Pentixather. ERT was performed 4 and 7 days after 
pre-therapy dosimetry, respectively. To prevent renal 
toxicity, 2 L of a solution containing arginine and 
lysine (25 g/L each) was co-infused in analogy to the 
joint IAEA, EANM, and SNMMI practical guidance 
on peptide receptor radionuclide therapy in 
neuroendocrine tumors [54]. Vital signs, complete 
blood count, and blood chemistry were documented 
during the infusion and within 7 days after 
administration. 
In order to enhance treatment effects, 
90Y-Pentixather therapy was followed by 
myeloablation by 153Sm-EDTMP (patient #1) and 
188Re-anti-CD66-directed antibodies (patients #2 and 
#3). 
Statistics 
Statistics were performed with GraphPad Prism 
(GraphPad Software, La Jolla, CA). A two-tailed 
student’s T-test was used to determine statistical 
significance (p value <0.05). Error bars represent 
mean ± standard error of the mean (SEM). Statistical 
significance is depicted as follows: * p<0.05, ** p<0.01, 
*** p<0.001. 
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